Andrographis 用于 上呼吸道感染
B 证据 至少一项随机试验支持这一结论，结果基本一致。Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'immunecited.com';
const params = 'ingredient\u003Dandrographis\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
结论
Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.
Key Study Findings
Randomized Controlled Trial
n=331
1.0 weeks
Double-blind
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common …
Dose: 200 mg/day
vs: placebo
Outcome: URTI symptom severity
效果: None
p = 0.034
研究人群: Participants with uncomplicated URTI
Review
A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead …
Dose: None
vs: None
Outcome: URTI symptom severity
效果: None
None
研究人群: COVID-19/URTI patients
Review
Plant-Based Support of Respiratory Health during Viral Outbreaks.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: None
Other
n=179
Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.
Dose: 60 mg
vs: placebo
Outcome: None
效果: None
p = 0.0053
研究人群: None
Meta-Analysis
n=1000
Safety of Andrographis paniculata: A systematic review and meta-analysis.
Dose: 95%
vs: control
Outcome: None
效果: None
None
研究人群: upper respiratory tract infection
Other
In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa.
Dose: 6 μg/mL
vs: Control group
Outcome: None
效果: None
None
研究人群: None
Key Statistics
7
研究数量
800
受试者
↑
Positive
B
等级
Referenced Papers
Complementary therapies in …
2023
6 次引用
Molecules (Basel, Switzerland)
2022
80 次引用
Journal of agricultural …
2022
9 次引用
Pharmacoepidemiology and drug …
2021
32 次引用
Journal of traditional …
2021
9 次引用
Brazilian journal of …
2020
45 次引用
Cell death & …
2019
160 次引用
Biomedicine & pharmacotherapy …
2019
103 次引用
Phytomedicine : international …
2010
107 次引用
Alternative medicine review …
2007
163 次引用
American journal of …
2006
51 次引用
Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy.
Systematic Review
Planta medica
2004
262 次引用
Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials.
Systematic Review
Journal of clinical …
2004
157 次引用
Primary care
2002
56 次引用
Journal of the …
1990
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- acute:
- 400 mg 3x/day for up to 7 days
- general:
- 200 mg standardized extract (30% andrographolides) 2x/day
上限： No established UL; short-term use (<14 days)
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| 200 mg/day | 1.0 weeks | Positive | 331 |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| 60 mg | -- | Positive | 179 |
| 95% | -- | Neutral | 1000 |
| 6 μg/mL | -- | Positive | -- |
| None | -- | Mixed | -- |
| 18 G | 4.0 weeks | Mixed | -- |
最佳服用时间： At first sign of symptoms; with meals
Safety & Side Effects
已报告的副作用
- ⚠ Gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Headache
- ⚠ Fatigue
- ⚠ Allergic reactions (rare)
- ⚠ Potential anti-fertility effects (high doses in animal studies)
已知相互作用
- ● Anticoagulant and antiplatelet drugs (may increase bleeding risk)
- ● Antihypertensive medications (additive blood pressure lowering)
- ● Immunosuppressant medications (may counteract immunosuppression)
可耐受最高摄入量： No established UL; short-term use (<14 days)
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Andrographis help with 上呼吸道感染?
Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support 上呼吸道感染 management. Our evidence grade is B (Good Evidence).
How much Andrographis should I take for 上呼吸道感染?
Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Andrographis?
Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Andrographis and 上呼吸道感染?
We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 上呼吸道感染
References
- [1] Jeffrey Pradeep Raj et al.. Complement Ther Med. 2023. Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, … doi:10.1016/j.ctim.2023.102934 PubMed
- [2] Aekkhaluck Intharuksa et al.. Molecules. 2022. A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery. doi:10.3390/molecules27144479 PubMed
- [3] Thirumurugan Rathinasabapathy et al.. J Agric Food Chem. 2022. Plant-Based Support of Respiratory Health during Viral Outbreaks. doi:10.1021/acs.jafc.1c06227 PubMed
- [4] Wiwan Worakunphanich et al.. Pharmacoepidemiol Drug Saf. 2021. Safety of Andrographis paniculata: A systematic review and meta-analysis. doi:10.1002/pds.5190 PubMed
- [5] Mikayel Narimanyan et al.. J Tradit Complement Med. 2021. Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study. doi:10.1016/j.jtcme.2021.06.001 PubMed
- [6] Moumita Majumdar et al.. Braz J Microbiol. 2020. In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa. doi:10.1007/s42770-019-00169-0 PubMed
- [7] Jian Gao et al.. Cell Death Dis. 2019. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. doi:10.1038/s41419-019-2195-8 PubMed
- [8] Jiashu Lu et al.. Biomed Pharmacother. 2019. A review for the neuroprotective effects of andrographolide in the central nervous system. doi:10.1016/j.biopha.2019.109078 PubMed
- [9] R C Saxena et al.. Phytomedicine. 2010. A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory … doi:10.1016/j.phymed.2009.12.001 PubMed
- [10] Mario Roxas et al.. Altern Med Rev. 2007. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. PubMed
- [11] Roxane R Carr et al.. Am J Health Syst Pharm. 2006. Complementary and alternative medicine for upper-respiratory-tract infection in children. doi:10.2146/ajhp040613 PubMed
- [12] Joanna Thompson Coon et al.. Planta Med. 2004. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. doi:10.1055/s-2004-818938 PubMed
- [13] N Poolsup et al.. J Clin Pharm Ther. 2004. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. doi:10.1046/j.1365-2710.2003.00534.x PubMed
- [14] Raja Jaber. Prim Care. 2002. Respiratory and allergic diseases: from upper respiratory tract infections to asthma. doi:10.1016/s0095-4543(01)00008-2 PubMed
- [15] A Leelarasamee et al.. J Med Assoc Thai. 1990. Undetectable anti-bacterial activity of Andrographis paniculata (Burma) wall. ex ness. PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。